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The global burden of scabies: a cross-sectional analysis from
the Global Burden of Disease Study 2015
Chante Karimkhani, Danny V Colombara, Aaron M Drucker, Scott A Norton, Roderick Hay, Daniel Engelman, Andrew Steer, Margot Whitfeld,
Mohsen Naghavi, Robert P Dellavalle

Summary

Background Numerous population-based studies have documented high prevalence of scabies in overcrowded
settings, particularly among children and in tropical regions. We provide an estimate of the global burden of scabies
using data from the Global Burden of Disease (GBD) Study 2015.
Methods We identified scabies epidemiological data sources from an extensive literature search and hospital insurance
data and analysed data sources with a Bayesian meta-regression modelling tool, DisMod-MR 2·1, to yield prevalence
estimates. We combined prevalence estimates with a disability weight, measuring disfigurement, itch, and pain
caused by scabies, to produce years lived with disability (YLDs). With an assumed zero mortality from scabies, YLDs
were equivalent to disability-adjusted life-years (DALYs). We estimated DALYs for 195 countries divided into 21 world
regions, in both sexes and 20 age groups, between 1990 and 2015.
Findings Scabies was responsible for 0·21% of DALYs from all conditions studied by GBD 2015 worldwide.
The world regions of east Asia (age-standardised DALYs 136·32), southeast Asia (134·57), Oceania (120·34),
tropical Latin America (99·94), and south Asia (69·41) had the greatest burden of DALYs from scabies.
Mean percent change of DALY rate from 1990 to 2015 was less than 8% in all world regions, except North America,
which had a 23·9% increase. The five individual countries with greatest scabies burden were Indonesia
(age-standardised DALYs 153·86), China (138·25), Timor-Leste (136·67), Vanuatu (131·59), and Fiji (130·91). The
largest standard deviations of age-standardised DALYs between the 20 age groups were observed in southeast
Asia (60·1), Oceania (58·3), and east Asia (56·5), with the greatest DALY burdens in children, adolescents, and
the elderly.
Interpretation The burden of scabies is greater in tropical regions, especially in children, adolescents, and elderly
people. As a worldwide epidemiological assessment, GBD 2015 provides broad and frequently updated measures of
scabies burden in terms of skin effects. These global data might help guide research protocols and prioritisation
efforts and focus scabies treatment and control measures.
Funding Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction
Scabies is a skin infestation caused by the mite
Sarcoptes scabiei that causes a pruritic skin eruption.1
Given that scabies transmission occurs with person-toperson contact, scabies is particularly prevalent in
resource-poor conditions and among children, and is
associated with insufficient access to health-care
subsidies. Scabies can occur in any setting but over the
past century has become less prevalent in temperate
regions and is more common in tropical, humid regions.
The predominant symptom of scabies infestation is
pruritus, which can be debilitating. Disruption of the
skin’s protective barrier function promotes secondary
bacterial infections, which can lead to additional,
potentially life-threatening, complications.2
Scabies has high prevalence in the tropics and large
cumulative morbidity. Recognition of scabies on the
global health agenda would increase awareness,
education, and research into diagnosis, treatment, and
www.thelancet.com/infection Vol 17 December 2017

prevention.3 In recognition, WHO recently formally
designated scabies as a neglected tropical disease.4
Previous investigations have reported on scabies
prevalence in specific, often low-resource, communities.5–8
A systematic review of 48 population-based studies found
the highest prevalence of scabies in Papua New Guinea,
Panama, and Fiji.9 However, beyond prevalence, the
extent to which scabies affects these communities is
unknown. In this paper, we provide estimates for the
global burden of scabies skin disease using data from the
Global Burden of Disease (GBD) study.
GBD provides a way to measure and compare health
loss from disease and injury across age, sex, location, and
time.10 GBD is based on formal, systematic, and
statistically rigorous analyses of effects of disease and
injuries on the health of populations. As an international
collaboration of more than 500 experts representing
30 countries, GBD 2015, the third iteration of the GBD
process, quantified the effects of 315 diseases and
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Research in context
Evidence before this study
We searched PubMed and Google Scholar databases on
July 15, 2017, for articles in English, Spanish, and French published
before June 30, 2017, using the key word “scabies” in the title or
abstract. Studies reported high-risk population-based national
and subnational estimates of scabies prevalence as well as
associated comorbidities such as psychological disorders.
However, previous attempts to estimate the global burden of
scabies skin infection were not available. The Global Burden of
Disease (GBD) Study 2015 assesses scabies epidemiological data
sources from a PubMed and Google Scholar literature search in
English and Spanish between 1980 and 2014. Prevalence and
incidence metrics were extracted from included sources and
analysed with a Bayesian meta-regression modelling tool. Burden
of disease is estimated as disability-adjusted life-years (DALYs).

injuries, including scabies, in 195 countries from
1990 to 2015.11 Disease burden is measured using the
disability-adjusted life-years (DALYs) metric, which
uniquely combines mortality (estimated using years of
life lost [YLL]) and morbidity (estimated using years lived
with disability [YLD]) components. By assessing disease
epidemiology on a global scale, GBD has the potential to
inform health policy and identify previously undervalued
or neglected conditions, such as scabies. The DALY
metric has broad clinical and research priority-setting
implications because it assesses both the prevalence and
impact of a disease and allows for comparison of various
diseases. This report presents GBD 2015 results on the
global burden of scabies.

Methods

Data collection

See Online for appendix
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Although details of GBD methods are extensively
published elsewhere,11–13 a brief overview specific to
scabies is presented here. The GBD category of scabies
is defined by the International Classification of Diseases
(ICD)-9 code 133 and ICD-10 code B86. A systematic
literature search was done and results were screened by
title and abstract to identify relevant studies, which then
underwent full-text screening and data extraction.
Studies published between 1980–2014 that provided data
on scabies incidence or prevalence, used samples
representative of the general population that were larger
than 100, and provided sufficient information on
methods to assess study quality as well as rules for
extracting uncertainty (standard error and 95% CI) were
included. Additionally, US health insurance claims data
from 2000, 2010, and 2012 were included (appendix).
38 studies on scabies prevalence in 84 countries and
three studies on scabies incidence in five countries were
included. All extracted scabies incidence and prevalence
datapoints were age-sex split and adjusted from primary
code to all code based on the claims data. These

Added value of this study
This study is the first global effort to measure the burden of
scabies. The greatest DALYs from scabies are in tropical
regions in east Asia, southeast Asia, Oceania, tropical
Latin America, and south Asia, especially in children,
adolescents, and the elderly.
Implications of all the available evidence
Increased global awareness of the burden from scabies will
promote international efforts for control of this preventable
disease. GBD provides high-quality estimates, which can be
used to set research priorities, promote discussion, and
ultimately, enact change, at local, national, and global
stages.

datapoints were then input into DisMod-MR 2.1, a
Bayesian meta-regression tool, which estimates scabies
prevalence by location, year, age, and sex. For the
DisMod-MR 2.1 analysis, scabies was modelled with
remission set between 1 and 9, corresponding to
durations of 6 weeks to 1 year, and mortality was assumed
to be zero, on the basis of available epidemiological data,
expert opinion, and previous GBD studies. As a proxy for
low levels of development, improved water source
(proportion of population with access to sufficient
quantities of water) was used as a country-level covariate.
For countries or regions with missing data, DisMod-MR
2.1 uses data in nearby countries, regions, and predictive
covariates to estimate data.
GBD divides disease prevalence into varying severity
levels. Scabies prevalence was categorised as one severity
level: disfigurement level 1 with itch or pain. This severity
level corresponded to the lay description: “The individual
has a slight visible physical deformity that is sometimes
sore or itchy. Observers notice the deformity, which
causes some worry and discomfort to the patient”.
The severity level was assigned on the basis of
recommendations from the GBD 2010 Skin Conditions
Expert Group.14 The severity prevalence estimates were
multiplied with a disability weight to generate YLDs for
each age-sex-country-year group. Disability weights,
which range from 0 (least disabling) to 1 (most disabling),
assessed the degree of disfigurement with itch or pain
from scabies in four population-based European surveys
and an open-access web-based survey of more than
60 890 respondents.15 The disability weight assigned to
scabies was 0·027 (95% CI 0·015–0·042). Notably, this
weighting only takes into account the effect of scabies on
the skin.
With scabies, YLL is assumed to be zero; YLDs were
equivalent to DALYs. DALY metrics are computed as
age-standardised and age-specific DALY rate per
100 000 persons and mean percent change in
www.thelancet.com/infection Vol 17 December 2017
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Panel: Global Burden of Disease regions and countries within each region
East Asia
China, North Korea, and Taiwan (province of China)
Oceania
American Samoa, Federated States of Micronesia, Fiji, Guam,
Marshall Islands, Northern Mariana Islands, Papua New Guinea,
Samoa, Solomon Islands, Tonga, and Vanuatu
Southeast Asia
Cambodia, Indonesia, Laos, Malaysia, Maldives, Mauritius,
Myanmar, Philippines, Sri Lanka, Seychelles, Thailand,
Timor-Leste, and Vietnam
South Asia
Bangladesh, Bhutan, India, Nepal, and Pakistan
Central Asia
Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan,
Mongolia, Tajikistan, Turkmenistan, and Uzbekistan
Central Europe
Albania, Bosnia and Herzegovina, Bulgaria, Croatia,
Czech Republic, Hungary, Macedonia, Poland, Romania, Serbia,
Slovakia, and Slovenia
Eastern Europe
Belarus, Estonia, Latvia, Lithuania, Moldova, Russia, and Ukraine
North Africa and Middle East
Afghanistan, Algeria, Bahrain, Egypt, Iran, Iraq, Jordan, Kuwait,
Lebanon, Libya, Morocco, Palestine, Oman, Qatar, Saudi Arabia,
Sudan, Syria, Tunisia, Turkey, United Arab Emirates, and Yemen
Western sub-Saharan Africa
Benin, Burkina Faso, Cameroon, Cape Verde, Chad, Côte d’Ivoire,
The Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali,
Mauritania, Niger, Nigeria, São Tomé and Príncipe, Senegal,
Sierra Leone, and Togo
Southern sub-Saharan Africa
Botswana, Lesotho, Namibia, South Africa, Swaziland, and
Zimbabwe

age-standardised DALY rate from 1990–2015. Scabies
estimates are made for both sexes, 20 age groups
(ranging from 0 days to >80 years), and 21 world regions
that include 195 countries and territories (panel).
Age-standardisation was based on GBD 2013 estimates
of the standard population structure from 2010–35
based on the most recent World Population Prospects
publication by the UN Population Division.16 To assess
variance of DALYs by age for a particular region,
standard deviation in each of the 20 age groups was
calculated. DALY metrics were organised and analysed
in Microsoft Excel, version 14.7.1. The Global Burden
of Disease Study is approved by the international
review board of the University of Washington until
March 25, 2018.
www.thelancet.com/infection Vol 17 December 2017

Eastern sub-Saharan Africa
Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar,
Malawi, Mozambique, Rwanda, Somalia, South Sudan, Tanzania,
Uganda, and Zambia
Central sub-Saharan Africa
Angola, Central African Republic, Congo (Brazzaville), Democratic
Republic of the Congo, Equatorial Guinea, and Gabon
Tropical Latin America
Brazil and Paraguay
Andean Latin America
Bolivia, Ecuador, and Peru
Central Latin America
Colombia, Costa Rica, El Salvador, Guatemala, Honduras,
Mexico, Nicaragua, Panama, and Venezuela
Caribbean
Antigua and Barbuda, The Bahamas, Barbados, Belize, Bermuda,
Cuba, Dominica, Dominican Republic, Grenada, Guyana, Haiti,
Jamaica, Puerto Rico, Saint Lucia, Saint Vincent and the
Grenadines, Suriname, Trinidad and Tobago, and Virgin Islands
Western Europe
Andorra, Austria, Belgium, Cyprus, Denmark, Finland, France,
Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg,
Malta, Netherlands, Norway, Portugal, Spain, Sweden,
Switzerland, and UK
Southern Latin America
Argentina, Chile, and Uruguay
North America
Canada, Greenland, and USA
Asia Pacific
Brunei, Japan, Singapore, and South Korea
Australasia
Australia and New Zealand

Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report. The corresponding author had full access to
all the data in the study and had final responsibility for
the decision to submit for publication.

Results
The GBD 2015 global prevalence of scabies in both sexes
was 204 151 715 (95% CI 177 533 726–237 466 220).13
Scabies caused 0·21% of DALYs from all conditions
studied by GBD 2015 globally. Global age-standardised
DALYs per 100 000 people from scabies was 71·11 (95% CI
39·77–116·03) for both sexes,11 and 70·58 (39·79–114·37)
for men and 71·72 (39·90–117·83) for women (data not
1249
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shown). Of 246 conditions comparatively ranked by GBD
2015, scabies ranked 101 in age-standardised global
DALYs, after adverse effects of medical treatment

(ranked 98), viral skin diseases (99), and
Haemophilus influenzae type b meningitis (100), and
before atrial fibrillation or flutter (102), acute lymphoid
leukaemia (103), and other transport injuries (104).
Global age-standardised DALYs in 20 age groups are
shown in table 1.
The five world regions with the greatest age-standardised
DALY burdens caused by scabies in decreasing order were
east Asia 136·32 (95% CI 75·83–222·35), southeast Asia
134·57 (74·62–223·64), Oceania 120·34 (68·10–194·84),
tropical Latin America 99·94 (56·75–163·50), and south
Asia 69·41 (39·73–112·65; figure 1). Mean percent changes
in age-standardised DALYs from 1990 to 2015 range from
21·87% (97·5% uncertainty interval [UI] 10·83 to 37·36)
in North America to –7·92% (–10·07 to –5·51) in eastern
sub-Saharan Africa (table 2). The regions with greatest
standard deviation of DALY burdens of the 20 age groups
were southeast Asia 60·1, Oceania 58·3, and east
Asia 56·5 (figure 2). The regions with the lowest standard
deviation of DALY burden of the 20 age groups were
Asia Pacific 2·2, North America 1·8, and western
Europe 0·6.
Of the 195 countries analysed, the ten countries
with the highest age-standardised scabies DALY
burdens per 100 000 people were Indonesia 153·86
(95% CI 86·48–254·02), China 138·25 (76·96–225·56),
Timor-Leste 136·67 (77·18–221·37), Vanuatu 131·59
(72·56–214·30), Fiji 130·91 (73·01–211·81), Cambodia
126·93 (70·61–214·55), Laos 124·96 (69·32–210·08),

Global DALYs per 100 000 people (95% CI)
0–6 days

2·35 (1·20–4·00)

7–27 days

10·97 (5·56–18·81)

28–364 days

73·72 (37·33–125·03)

1–4 years

116·30 (59·28–205·71)

5–9 years

99·25 (48·95–183·04)

10–14 years

95·22 (46·24–164·65)

15–19 years

101·88 (50·78–177·68)

20–24 years

96·76 (46·15–176·88)

25–29 years

73·28 (35·03–141·91)

30–34 years

53·20 (26·13–96·12)

35–39 years

47·66 (23·14–86·20)

40–44 years

50·24 (23·54–89·20)

45–49 years

49·94 (24·52–92·29)

50–54 years

44·63 (21·98–83·38)

55–59 years

39·94 (19·31–69·18)

60–64 years

38·80 (19·51–67·56)

65–69 years

40·02 (20·31–71·07)

70–74 years

42·80 (21·40–76·67)

75–79 years

52·34 (25·26–92·46)

≥80 years

46·38 (24·03–78·30)

DALYs=disability-adjusted life-years.

Table 1: Global DALYs from scabies skin infection by age
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Figure 1: Global 2015 scabies age-standardised DALYs per 100 000 people in males, females, and both sexes
DALYs=disability-adjusted life-years.
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Myanmar 124·46 (68·50–208·53), Vietnam 123·30
(68·41–207·56), and Seychelles 122·99 (67·38–203·58;
figure 3).

Mean percent change in
DALYs 1990–2015 (97·5% UI)
Global

–5·38 (–7·81 to –3·14)

North America

23·87 (10·83 to 37·36)

Southern Latin America

0·69 (–5·38 to –6·99)

Western Europe

0·32 (–4·57 to 5·46)

Australasia

0·02 (–4·97 to 5·22)

Central Europe

Discussion
Our analysis of GBD 2015 shows that the greatest burden
from scabies is in countries in east Asia, southeast Asia,
Oceania, and tropical Latin America. This is supported
by previous prevalence studies, which have reported high
prevalence of scabies in hot, tropical areas where
overcrowding facilitates the rapid spread of the scabies
mite.5–9 The burden of scabies over the human lifespan
has differing patterns in regions with high or low scabies
burden. In east and southeast Asia, the regions with
greatest scabies burden, DALY burden is highest in
children aged 1–4 years, followed by a high but gradually
decreasing burden from age 5 to 24 years. DALY burdens
decrease substantially during adulthood, before
increasing slightly after the age of 70 years. This pattern
is much less pronounced in North America and western
Europe, which are the regions with the lowest overall
scabies burdens. In these low-burden regions, scabies
prevalence is more evenly distributed across all age
groups, including elderly people, in whom outbreaks of
infestations have occurred in care homes.17,18
When comparing scabies burden by sex, most world
regions had an even distribution between males and
females. The greatest discrepancies were in eastern
Europe and central Europe, where the ratios of

0·06 (–2·64 to 2·32)

Asia Pacific

–0·29 (–4·21 to 4·22)

Eastern Europe

–0·83 (–4·78 to 3·83)

Caribbean

–0·84 (–3·75 to 1·80)

South Asia

–1·12 (–5·23 to 3·17)

Central Latin America

–1·30 (–3·83 to 2·33)

Andean Latin America

–1·51 (–5·34 to 2·54)

Southern sub-Saharan Africa

–1·54 (–5·58 to 2·75)

Central Asia

–1·79 (–4·69 to 1·00)

Tropical Latin America

–2·55 (–7·21 to 2·26)

Central sub-Saharan Africa

–2·62 (–6·89 to 2·19)

Southeast Asia

–2·66 (–6·15 to 1·02)

North Africa and Middle East

–2·86 (–5·17 to –0·09)

East Asia

–3·18 (–7·71 to 1·76)

Western sub-Saharan Africa

–7·16 (–10·25 to –3·45)

Oceania

–7·12 (–10·80 to –3·04)

Eastern sub-Saharan Africa

–7·92 (–10·07 to –5·51)

Data are for both sexes from 1990 to 2015 globally and by world region.
UI=uncertainty interval. DALYs=disability-adjusted life-years.

Table 2: Mean percent change in age-standardised DALYs
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Figure 2: Scabies DALYs per
100 000 people by age and
world region
DALYs=disability-adjusted lifeyears.
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Figure 3: World map of scabies age-standardised disability-adjusted life-years per 100 000 people
ATG=Antigua and Barbuda. BRB=Barbados. COM=Comoros. DMA=Dominica. FJI=Fiji. FSM=Federated States of Micronesia. GRD=Grenada. KIR=Kiribati. LCA=Saint Lucia. MDV=Maldives.
MHL=Marshall Islands. MLT=Malta. MUS=Mauritius. SGP=Singapore. SLB=Solomon Islands. SYC=Seychelles. TLS=Timor-Leste. TON=Tonga. TTO=Trinidad and Tobago. VCT=Saint Vincent and the
Grenadines. VUT=Vanuatu. WSM=Samoa.

age-standardised DALYs in males to females were 1·23
(eastern Europe) and 0·77 (central Europe). With the
exception of North America, age-standardised DALY
burdens from 1990 to 2015 across all 21 world regions did
not change by more than 8%. North America had the
largest mean percent change in age-standardised DALYs
from 1990 to 2015, with an increase of 23·8%.
Although beyond the scope of this GBD analysis,
subnational differences in the burden of scabies have
previously been identified. For example, Aboriginal
Australian communities have much higher prevalence
of scabies than the non-indigenous population.19
Several subnational regions within Ethiopia have been
particularly affected by natural disasters such as the
El Niño weather phenomenon, leading to severe drought
and scabies outbreaks.20 Additionally, conflicts in areas
such as Africa and the Middle East have led to increasing
numbers of refugees seeking asylum in Europe. A recent
investigation of a tertiary care hospital in Switzerland
found high incidence of co-infection of multiple
infectious diseases with scabies in African refugees.21
The potential impact of high-quality big data on health
and disease is enormous. As the world becomes
1252

increasingly globalised, more and more attention is paid
to diseases that disproportionately affect vulnerable
populations. Although still highly neglected, renewed
efforts are now directed toward the global control
of scabies. The International Alliance for the Control of
Scabies is a global network committed to the control of
human scabies and the promotion of health and
wellbeing of all those living in affected communities.22
The availability of high-quality data on scabies burden,
such as those provided by GBD 2015, is needed to enact
local, national, and global change.
Funding bodies often consider diseases that dis
proportionately affect particular populations in their
allocation of the limited financial resources. Research
interest has recently increased in scabies diagnosis
and treatment, and population-based interventions. A
particularly notable area that warrants further research
and implementation is mass drug administration
(MDA) for community-wide control of scabies. A recent
comparative study done on several Fijian islands over
12 months showed superior effectiveness of oral
ivermectin MDA over topical permethrin in the reduction
of scabies prevalence.23
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The GBD 2015 scabies estimates have some limitations.
One notable consideration is the fact that the GBD
analysis data on secondary bacterial infection due to
Streptococcus pyogenes and Staphylococcus aureus, which is
causally related to the presence of the scabies mite, are not
included. Complications of scabies such as impetigo, local
and systemic bacterial infections, glomerulonephritis, and
rheumatic fever are also not covered. Data from Fiji
showed that the attributable risk of scabies infection on
impetigo was 94%.5 Additionally, the variant of crusted
scabies, which has very high mortality, is not considered
by GBD. Thus, the GBD assumption that scabies has no
mortality (YLL) estimation is entirely focused on the direct
skin infection of this condition.
Another crucial deficit is poor case ascertainment in
low-resource settings where scabies is most prevalent,
including patient presentation, proper disease diagnosis,
and adequate coding of scabies. For regions that have
missing data, estimates are derived from data in nearby
countries, regions, and predictive covariates. As an
example, since there are no data sources on scabies
epidemiology for sub-Saharan Africa, the estimates for
this region are based on global estimates and the
covariate of improved water source. The included scabies
data sources used in GBD 2015 include US claims
reports; however, the USA has a low scabies burden that
might have distorted overall global results.
The GBD literature search was done only using
PubMed and Google Scholar databases because of time
and resource constraints. Thus, regional database
searches were not done and the literature search was
limited to English and Spanish languages. Since the
GBD scabies method does not easily account for
outbreaks or particular subgroups (other than age, sex,
and geography), certain high-risk groups (eg, homeless
populations in the USA) would slightly raise the overall
scabies burden estimate for the larger population of
which they are a part. The GBD disability weight method
is founded on the principle that no disability doublecounting occurs. Thus, although the skin effects of
scabies can cause more notable morbidity such as sleep
deprivation, mental disorders, and renal problems than
all other skin conditions, the disability weight for scabies
assesses only the direct effect of skin infection and the
GBD 2010 Skin Conditions Expert Group assigned it the
severity of disfigurement level 1. A final limitation is that
GBD modelling does not take into account various
diagnostic methods such as different case definitions
that might affect diagnosis estimates.
Scabies burden is greatest in tropical regions within east
Asia, southeast Asia, Oceania, and tropical Latin America,
especially in children, adolescents, and the elderly.
Although similar global epidemiological studies are
scarce, our findings agree with the systematic reviews and
population-level and country-level investigations that we
found.5–9 GBD 2015 allows for a high-quality, objective
measure of scabies burden with regards to its effects on
www.thelancet.com/infection Vol 17 December 2017

the skin. The premise of GBD is that every human being
deserves to live a long life in full health, as described by
the IHME. Scabies is an impediment to that goal,
particularly in countries with high prevalence and poor
access to effective treatment.
Of particular concern is the consistency of the DALY
burden from scabies over the past 25 years from
1990 to 2015. In most world regions, no change indicates
that scabies burden remains low. However, no change in
high-burden regions such as east Asia, southeast Asia,
Oceania, and tropical Latin America might indicate
inadequate treatment and control measures. Disease
treatment and control is particularly difficult, because
economically disadvantaged populations are prone to
overcrowding and are less likely to afford proper
medications or seek appropriate medical attention. Recent
studies suggest that MDA campaigns hold the greatest
benefit for these regions.

For the IHME principles see
http://www.healthdata.org/
about/our-principles
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